ULTRAPLACAD industrial prototype for early cancer diagnosis

The ULTRAPLACAD prototype integrating the novel surface plasmon resonance imaging (NESPRI) and plasmon-enhanced fluorescence (PEFSI) sensing technologies has been assembled. Functional tests are in progress. In parallel, the integrated cartridges for in-vitro cancer detection are under development using high volume manufacturing methods.

In ULTRAPLACAD many markers can be measured simultaneously. ULTRAPLACAD diagnostic platform will improve early diagnostic testing and will enable more specific selection of patients for therapy, as well as therapy monitoring from liquid biopsies, thus reducing invasive procedures and improving patient management.

During the next year, the ULTRAPLACAD platform including the assays for the detection of mutated DNAs, microRNAs and tumor autoantibodies (a-TAAs) will be finalized and validated. Please, stay updated about the upcoming project results (www.ultraplacad.eu).